Impurity profile study of zaleplon

被引:15
作者
Bharathi, Ch.
Prabahar, K. Joseph
Prasad, Ch. S.
Kumar, M. Saravana
Magesh, S.
Handa, V. K.
Dandala, Ramesh
Naidu, A.
机构
[1] APL Res Ctr, Hyderabad 500072, Andhra Pradesh, India
[2] JNT Univ, Dept Chem, Hyderabad 500072, Andhra Pradesh, India
关键词
zaleplon; impurities; isolation; preparative HPLC; characterization;
D O I
10.1016/j.jpba.2007.01.051
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Zaleplon is a pyrazolopyrimidine derivative and possesses sedative and hypnotic properties. Seven unknown impurities in zaleplon bulk drug at levels below 0.1% were detected by reverse-phase high performance liquid chromatography (HPLC). The starting material, 3-amino-4-cyanopyrazole and an intermediate, N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]-phenyl]-N-ethylacetamide (DOPEA) were also present in the sample at a level below 0.1%. The molecular weights of impurities were determined by LC-MS analysis. These impurities were isolated from crude samples of zaleplon using reverse-phase preparative HPLC. Based on the spectral data the structures of these impurities were characterized as, N-(3-(3-(4-amino-2H-pyrazolo [3,4-d]pyrimidin-6-yl) pyrazolo[1,5-a] pyrimidin-7yl)phenyl)-N-ethylacetamide (impurity 1); N-[3-(3-carboxamidopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide (impurity II); N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]acetamide (impurity III); N-[3-(3-cyanopyrazolo [1,5-a]pyrimidin-7-yl)phenyl]-N-methylacetamide (impurity IV); N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-5-yl)phenyl]-N-ethylacetamide (impurity V); N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7yl)phenyl]-N-ethylamine (impurity VI);N-[3-(3-cyano-6-[(E)-3-((N-ethyl-N-acetyl)amino)phenyl-3-oxoprop-1-enyl] pyrazolo[1,5-a]pyrimidin-7yl)phenyl]-N-ethylacetamide (impurity VII). Structural elucidation of all impurities by spectral data (H-1 NMR, C-13 NMR, MS and IR) and formation of these impurities are discussed in detail. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:101 / 109
页数:9
相关论文
共 10 条
[1]  
[Anonymous], 2002, ICH GUIDELINE Q3A R
[2]  
DENG M, 2004, J YAOWU FENXI ZAZHI, V24, P611
[3]   Development and validation of a high-performance liquid chromatography-electrospray ionization-mass spectrometry assay for the determination of zaleplon in human plasma [J].
Feng, F ;
Jiang, JJ ;
Dai, H ;
Wu, J .
JOURNAL OF CHROMATOGRAPHIC SCIENCE, 2003, 41 (01) :17-21
[4]   Reversed-phase liquid chromatographic determination of zaleplon in human plasma and its pharmacokinetic application [J].
Foda, NH ;
Elbary, AA ;
El-Gazayerly, O .
ANALYTICAL LETTERS, 2006, 39 (09) :1891-1905
[5]   Determination of zaleplon and zolpidem by liquid chromatography-turbo-ionspray mass spectrometry: application to forensic cases [J].
Giroud, C ;
Augsburger, M ;
Menetrey, A ;
Mangin, P .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 789 (01) :131-138
[6]   Separation and identification of zaleplon metabolites in human urine using capillary electrophoresis with laser-induced fluorescence detection and liquid chromatography-mass spectrometry [J].
Horstkötter, C ;
Schepmann, D ;
Blaschke, G .
JOURNAL OF CHROMATOGRAPHY A, 2003, 1014 (1-2) :71-81
[7]  
Korodi F., 2002, WO Patent, Patent No. [02/100828, 02100828]
[8]  
KORYCINSKA M, 2003, Patent No. 03095456
[9]  
[李青翠 Li Qingcui], 2004, [中国药学杂志, Chinese Pharmaceutical Journal], V39, P220
[10]   High-performance liquid chromatography-atmospheric pressure chemical ionisation-mass spectrometry determination of zaleplon in human plasma [J].
Zhang, BB ;
Zhang, ZJ ;
Tian, Y ;
Xu, FG ;
Chen, Y .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2006, 40 (03) :707-714